Dishman Carbogen Amc
Ticker > Company >

Dishman Carbogen Amc share price

Dishman Carbogen Amcis Ltd.

NSE: DCAL BSE: 540701 SECTOR: Pharmaceuticals & Drugs  1.06 L   204   20

239.15
-0.50 (-0.21%)
NSE: Today, 11:14 AM

Price Summary

Today's High

₹ 244.4

Today's Low

₹ 236

52 Week High

₹ 307.98

52 Week Low

₹ 161.21

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3749.47 Cr.

Enterprise Value

₹ 4263.55 Cr.

No. of Shares

15.68 Cr.

P/E

0

P/B

0.93

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  257.07

CASH

₹ 9.9 Cr.

DEBT

₹ 523.98 Cr.

Promoter Holding

59.32 %

EPS (TTM)

₹  -0.63

Sales Growth

-18.68%

ROE

-1.87 %

ROCE

-0.75%

Profit Growth

-29.79 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-18.68%
3 Year17.79%
5 Year-9.84%

Profit Growth

1 Year-29.79%
3 Year18.68%
5 Year-206.41%

ROE%

1 Year-1.87%
3 Year-1.32%
5 Year-1.59%

ROCE %

1 Year-0.75%
3 Year-0.83%
5 Year-0.6%

Debt/Equity

0.1293

Price to Cash Flow

155.13

Interest Cover Ratio

-0.5105

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 59.32 0.00
Mar 2025 59.32 0.00
Dec 2024 59.32 0.00
Sep 2024 59.32 0.00
Jun 2024 59.32 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 17.7864412208737% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 63.9983 days.
  • The company has a high promoter holding of 59.32%.

 Limitations

  • Company has a poor ROE of -1.32204235755562% over the past 3 years.
  • Company has a poor ROCE of -0.828211859911797% over the past 3 years
  • Company has low Interest coverage ratio of -0.5105.
  • Company has high debtor days of 184.2561.
  • The company has a low EBITDA margin of 3.7117373409443% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 41.4749.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 111.26 103.41 93.29 97.04 106.1
Total Expenditure 99.69 88.51 79.89 74.08 85.57
Operating Profit 11.57 14.9 13.4 22.96 20.53
Other Income -3.21 11.59 23.93 -8.01 5.47
Interest 15.87 15.73 15.59 17.77 21.31
Depreciation 26.12 16.32 16.3 16.48 16.1
Exceptional Items 0 0 0 0 0
Profit Before Tax -33.63 -5.56 5.44 -19.3 -11.41
Tax -2.51 -2.09 -8.81 -6.02 -4.04
Profit After Tax -31.12 -3.47 14.25 -13.28 -7.37
Adjusted EPS (Rs) -1.98 -0.22 0.91 -0.85 -0.47

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 580.74 200.32 306.61 402.55 327.35
Total Expenditure 407.18 253.11 272.82 394.79 320.55
Operating Profit 173.56 -52.79 33.79 7.76 6.8
Other Income 69.57 66.29 66.11 52.16 63.05
Interest 47.02 34.17 37.23 57.92 68.19
Depreciation 140.65 141.35 140.07 96.2 101.61
Exceptional Items 0 0 -5.91 -2 -3.05
Profit Before Tax 55.46 -162.02 -83.31 -96.2 -103
Tax 16.94 64.12 -52.84 -37.33 -26.59
Net Profit 38.52 -232.81 -31.55 -58.87 -76.41
Adjusted EPS (Rs.) 2.46 -14.42 -1.94 -3.75 -4.87

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 31.38 31.36 31.36 31.36 31.36
Total Reserves 4764.47 4643.26 4200.42 4082.95 4021.22
Borrowings 137.9 144.41 134.42 162.57 157.37
Other N/C liabilities 356.7 348.96 444.04 409.68 395.1
Current liabilities 620.44 530.88 551.19 641.6 618.73
Total Liabilities 5910.89 5698.87 5361.43 5328.16 5223.78
Assets
Net Block 1632.53 1509.65 1355.98 1382.3 1415.63
Capital WIP 57.14 79.36 114.12 141.88 73.35
Intangible WIP 31.71 41.84 3.65 1.01 0.7
Investments 2843.1 2814.87 2811.09 2837.36 2834.26
Loans & Advances 576.27 529.74 310.14 315.19 311.95
Other N/C Assets 5.45 0.35 0.66 0.81 0.67
Current Assets 764.69 723.06 765.79 649.61 587.22
Total Assets 5910.89 5698.87 5361.43 5328.16 5223.78
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 55.46 -168.69 -84.39 -96.2 -103
Adjustment 135.32 128.11 117.32 100.96 116.86
Changes in Assets & Liabilities 24.14 46.25 200.55 -54.11 11.53
Tax Paid -18.24 -7.18 -6.13 -3.55 -1.22
Operating Cash Flow 196.68 -1.51 227.35 -52.9 24.17
Investing Cash Flow -74.3 62.07 -172.67 40.71 96.57
Financing Cash Flow -124.07 -70.53 -46.16 1.38 -130.76
Net Cash Flow -1.69 -9.97 8.52 -10.81 -10.02

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 59.32 59.32 59.32 59.32 59.32
adimans technologies llp ... - - - - 59.32
adimans technologies llp 59.32 59.32 59.32 59.32 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 40.68 40.68 40.68 40.68 40.68
hbm healthcare investment... 3.55 3.55 3.55 3.57 3.57
investor education and pr... - 0.02 0.02 0.02 0.02
llp 0.39 0.30 0.81 0.79 0.73
massachusetts institute o... 1.95 1.95 1.95 2.27 2.28
mukul mahavir agrawal 5.74 5.50 5.50 5.50 5.50
investor education and pr... 0.02 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit FITCH
Credit FITCH
Credit INDIA RATINGS & RESEARCH
Credit FITCH
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research BOB Capital Market
Research Nirmal Bang Institutional
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q3FY24
Concall Q3FY24
Concall Q3FY23
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

USFDA completes inspection at Dishman Carbogen Amcis’ facility in Naroda 16 Jun, 9:48 AM Dishman Carbogen Amcis’ arm enters into co-investment agreement with Japanese customer 6 Jun, 3:47 PM Dishman Carbogen Amcis informs about press release 26 May, 5:44 PM Dishman Carbogen Amc - Quaterly Results 21 May, 11:12 PM Dishman Carbogen Amc - Quaterly Results 21 May, 11:12 PM Dishman Carbogen Amcis’ arm gets drug manufacturing license from NMPA for Shanghai facility 22 Apr, 11:52 AM Dishman Carbogen Amcis raises Rs 50 crore through NCDs 26 Mar, 3:51 PM Dishman Carbogen Amcis’ arm receives Certificate of GMP Compliance form ANSM 20 Mar, 1:00 PM Dishman Carbogen Amc - Quaterly Results 12 Feb, 8:05 PM Dishman Carbogen Amc - Quaterly Results 12 Feb, 8:05 PM Dishman Carbogen Amcis’ arm completes Swissmedic inspection of Vionnaz facility 10 Jan, 2:58 PM Dishman Carbogen Amcis informs about presentation 14 Nov, 9:44 AM Dishman Carbogen Amc - Quaterly Results 13 Nov, 11:42 PM Dishman Carbogen Amc - Quaterly Results 13 Nov, 11:42 PM Dishman Carbogen Amcis informs about confirmation certificate 10 Oct, 5:08 PM Dishman Carbogen Amcis informs about closure of trading window 25 Sep, 5:21 PM Dishman Carbogen Amcis informs about closure of trading window 25 Sep, 5:14 PM Dishman Carbogen Amcis informs about earnings call transcript 22 Aug, 5:18 PM Dishman Carbogen Amc - Quaterly Results 13 Aug, 8:30 PM Dishman Carbogen Amc - Quaterly Results 30 May, 11:40 PM Dishman Carbogen Amc - Quaterly Results 30 May, 11:40 PM Dishman Carbogen Amcis planning to raise funds via NCDS 25 May, 2:02 PM Dishman Carbogen Amc - Quaterly Results 14 Feb, 7:01 PM Dishman Carbogen Amc - Quaterly Results 14 Feb, 7:01 PM Dishman Carbogen Amcis informs about disclosure 3 Feb, 1:46 PM Dishman Carbogen Amc - Quaterly Results 8 Nov, 7:21 PM Dishman Carbogen Amc - Quaterly Results 8 Nov, 7:21 PM Dishman Carbogen Amcis informs about closure of trading window 22 Sep, 5:19 PM Dishman Carbogen Amc - Quaterly Results 9 Aug, 6:12 PM Dishman Carbogen Amc - Quaterly Results 9 Aug, 6:12 PM Dishman Carbogen Amc - Quaterly Results 23 May, 4:57 PM Dishman Carbogen Amc - Quaterly Results 23 May, 4:57 PM Dishman Carbogen Amcis informs about board meeting 15 May, 5:16 PM Dishman Carbogen Amcis’ arm completes USFDA’s inspection at Switzerland manufacturing site 16 Feb, 4:58 PM Dishman Carbogen Amcis informs about transcript of earnings call 15 Feb, 4:32 PM Dishman Carbogen Amc - Quaterly Results 10 Feb, 4:12 PM Dishman Carbogen Amc - Quaterly Results 10 Feb, 4:12 PM Dishman Carbogen Amc - Quaterly Results 10 Feb, 4:12 PM Dishman Carbogen Amcis informs about board meeting 12 Jan, 4:48 PM Dishman Carbogen Amcis informs about credit rating 22 Dec, 3:25 PM Dishman Carbogen Amc - Quaterly Results 11 Nov, 3:47 PM Dishman Carbogen Amc - Quaterly Results 11 Nov, 3:47 PM Dishman Carbogen Amcis’ arm completes Swissmedic inspection of facility in Switzerland 29 Sep, 12:17 PM Dishman Carbogen Amcis informs about conference call 10 Aug, 4:58 PM Dishman Carbogen Amcis informs about investor presentation 10 Aug, 12:25 PM Dishman Carbogen Amc - Quaterly Results 9 Aug, 6:39 PM Dishman Carbogen Amc - Quaterly Results 9 Aug, 6:39 PM Dishman Carbogen Amcis informs about closure of trading window 28 Jun, 3:35 PM Dishman Carbogen Amcis informs about newspaper advertisement 23 Jun, 4:53 PM Dishman Carbogen Amcis informs about annual secretarial compliance report 30 May, 1:50 PM

Dishman Carbogen Amc Stock Price Analysis and Quick Research Report. Is Dishman Carbogen Amc an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Dishman Carbogen Amc and its performance over the period of time. Dishman Carbogen Amc stock price today is Rs 239.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Dishman Carbogen Amc cash from the operating activity was Rs 24.17 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Dishman Carbogen Amc has a Debt to Equity ratio of 0.1293 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Dishman Carbogen Amc , the EPS growth was -29.7936 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Dishman Carbogen Amc has OPM of 2.07728730716359 % which is a bad sign for profitability.
     
  • ROE: Dishman Carbogen Amc have a poor ROE of -1.8712 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Dishman Carbogen Amc is Rs 239.15. One can use valuation calculators of ticker to know if Dishman Carbogen Amc share price is undervalued or overvalued.
Last Updated on:
Brief about Dishman Carbogen Amc

Dishman Carbogen Amcis Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Dishman Carbogen Amcis Ltd. is a leading global contract research and manufacturing organization (CRMO) that focuses on the development and manufacturing of intermediates, APIs (active pharmaceutical ingredients), and finished dosage forms. With a rich history spanning several decades, Dishman Carbogen Amcis has established itself as a trusted partner in the pharmaceutical and life sciences industry.

Dishman Carbogen Amcis Ltd. - Share Price

Explore the latest share price of Dishman Carbogen Amcis Ltd. and track its performance in the stock market. Our website offers a user-friendly interface that allows you to stay updated with real-time stock prices, historical data, and key performance indicators.

Dishman Carbogen Amcis Ltd. - Balance Sheet

Gain insights into Dishman Carbogen Amcis Ltd.'s financial position through a comprehensive analysis of its balance sheet. Assess the company's assets, liabilities, and shareholders' equity to evaluate its overall financial health.

Dishman Carbogen Amcis Ltd. - Annual Report

Access Dishman Carbogen Amcis Ltd.'s annual reports on our website to review their performance throughout the year. These reports provide a detailed overview of the company's operations, financial results, and strategic initiatives. Stay informed about the company's achievements, challenges, and future prospects.

Dishman Carbogen Amcis Ltd. - Dividend

Discover Dishman Carbogen Amcis Ltd.'s dividend history and track the company's dividend payouts over time. Our website provides dividend information, including the dividend yield and dividend payment dates, enabling you to make informed investment decisions.

Dishman Carbogen Amcis Ltd. - Quarterly Result

Stay updated with Dishman Carbogen Amcis Ltd.'s quarterly results and analyze the company's financial performance for each reporting period. Our website offers downloadable quarterly reports that provide a comprehensive overview of the company's revenue, expenses, and profitability.

Dishman Carbogen Amcis Ltd. - Stock Price

Monitor Dishman Carbogen Amcis Ltd.'s stock price and track its movement in the market. Our website offers interactive stock charts and technical analysis tools to help you analyze historical price trends and make informed investment decisions.

Dishman Carbogen Amcis Ltd. - Price Chart

Our website provides detailed price charts for Dishman Carbogen Amcis Ltd., allowing you to visualize the stock's price movement over different timeframes. Analyze historical price patterns, spot trends, and identify potential investment opportunities using our pre-built screening tools.

Dishman Carbogen Amcis Ltd. - News

Stay informed about recent developments and news related to Dishman Carbogen Amcis Ltd. Our website curates the latest news articles and press releases, providing you with up-to-date information on the company's activities, collaborations, regulatory updates, and more.

Dishman Carbogen Amcis Ltd. - Concall Transcripts

Access Dishman Carbogen Amcis Ltd.'s con call transcripts on our website. These transcripts provide detailed insights into the company's conference calls with investors, allowing you to understand the management's perspective on the company's performance, future plans, and industry trends.

Dishman Carbogen Amcis Ltd. - Investor Presentations

Explore Dishman Carbogen Amcis Ltd.'s investor presentations to gain deeper insights into the company's strategy, market positioning, and growth potential. Our website provides downloadable investor presentations that showcase the company's achievements, financial highlights, and future outlook.

Dishman Carbogen Amcis Ltd. - Promoters

Learn about Dishman Carbogen Amcis Ltd.'s promoters and their contribution to the company's growth and success. Understand their vision, leadership, and strategic direction, which play a crucial role in shaping the company's future.

Dishman Carbogen Amcis Ltd. - Shareholders

Explore Dishman Carbogen Amcis Ltd.'s shareholder structure and understand the ownership pattern of the company. Gain insights into the major shareholders, institutional investors, and public investors who hold shares in Dishman Carbogen Amcis Ltd.

At our website, we offer pre-built screening tools that enable long-term stock investors to perform detailed stock analysis. Our tools, such as DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis, allow you to calculate fair value, assess the company's financial health, and make informed investment decisions.

Furthermore, we provide downloadable annual reports, concall transcripts, investor presentations, credit ratings, and research reports for Dishman Carbogen Amcis Ltd., ensuring that you have access to comprehensive information to aid your stock analysis.

Please note that the content is written in a technical tone to cater to the needs of long-term stock investors seeking in-depth stock analysis. 

Dishman Carbogen Amcis Balance Sheet Analysis

Dishman Carbogen Amcis Equity and Liabilities

Analyzing the balance sheet of Dishman Carbogen Amcis, we notice a slight decrease in the company's total liabilities from Rs. 5,910.89 Cr. in March 2020 to Rs. 5,223.78 Cr. by March 2024. The share capital remains stable at Rs. 31.36 Cr. from March 2021 onwards. However, there's a noticeable decline in total reserves, reducing from Rs. 4,764.47 Cr. in March 2020 to Rs. 4,021.22 Cr. by March 2024. Borrowings and other non-current liabilities exhibit fluctuation but demonstrate a decrease in the forecasted year 2024 compared to 2020.

Dishman Carbogen Amcis Assets

On the asset front, Dishman Carbogen Amcis's total assets decreased alongside their liabilities, signifying a balance. The net block and capital work in progress (WIP) reflect a downward trend initially but pick up by March 2023. However, intangible WIP drops significantly by March 2024. Investments remain relatively stable around Rs. 2,800 Cr., indicating cautious financial management. Current assets have seen a decline from Rs. 764.69 Cr. in March 2020 to Rs. 587.22 Cr. by March 2024, signaling a potential reevaluation of liquidity strategies.

This analysis reflects on the standalone balance sheet of Dishman Carbogen Amcis and aids in understanding its financial posture without delving into buy or sell recommendations. It's crucial for investors to examine such data when screening stocks or looking into sectors that the company operates within, including any related to NSE BSE indices or IPOs.

Read More
X